In recent times, the storm of retreating “Shen medicine†is sweeping across the country, and major hospitals in Beijing (third-level hospitals) are also active. Recently, the Beijing Municipal Health and Family Planning Commission issued the “Notice on Strengthening the Management of Keyly Monitored Drugs in Medical Institutions†(hereinafter referred to as the “Noticeâ€) to the district and county health planning committees and tertiary hospitals in the territories. The “Notice†clarifies that non-treatment must be necessary and clinical efficacy Drugs with insufficient evidence are listed as “key monitoring drugsâ€. All medical institutions must establish relevant catalogues and enter the top 20 key monitoring drugs for medical institutions for three consecutive months. Measures such as restriction or suspension will be adopted. According to the relevant person in charge of the Beijing Municipal Health Planning Commission, the main characteristics of the key monitoring drugs are: non-treatment of certain diseases, insufficient evidence of clinical efficacy, lack of recommendation for the diagnosis and treatment of authoritative diseases, or lack of pharmacoeconomic advantages, and dosage Large or high purchase amount. For such drugs, all medical institutions shall formulate a catalogue of “key monitoring drugsâ€. In the top 100 drugs used by each institution, combined with the characteristics of each department of the institution, according to the principles of effective, safe and economic rational use of drugs, The organization focuses on monitoring the drug list, and the number of catalogues is not less than 15 (including chemical drugs, proprietary Chinese medicines and biological drugs). For the key monitoring drugs that have entered the top 20 sales of medical institutions for three consecutive months, measures such as interviewing, restricting use or stopping sales, etc., all medical institutions should strengthen the selection, procurement, prescription, adjustment, clinical application of key monitoring drugs. Evaluation and other aspects of monitoring, and further improve the super-normal warning mechanism for key monitoring drug catalogs. At the same time, the catalogue is dynamically monitored and adjusted, and is updated and updated according to the drug usage every year. For the supervision and management of key monitoring drugs, the "Notice" requires that the principal responsible persons of various medical institutions shall be the first responsible persons for the key monitoring and drug management of the institution, and the administrative departments of health and family planning at all levels shall make full use of information technology to monitor drugs for medical institutions. Monitoring the catalogue and clinical use, and organizing on-site supervision and inspection in a timely manner. Medical institutions that fail to implement the key monitoring drug management work may take measures such as notification, rectification within a time limit, and talks with the main person in charge of the organization. Medical institutions that are still not in place for rectification and implementation must be held accountable for the responsibility of the responsible person. Attached to the Beijing Municipal Health and Family Planning Commission to strengthen the management of key monitoring drugs in medical institutions District Health and Family Planning Commission, each tertiary hospital: According to the "Notice of the Beijing Municipal People's Government on the Implementation Plan for the Separate Comprehensive Reform of Printing and Dispensing Medicine" (Jing Zheng Fa [2017] No. 11) and the National Health and Family Planning Commission and other 9 ministries and commissions on the issue of correcting the purchase and sale of medical products and medical services in 2017 Notice of the main points of special governance work (National Health Medical Letter [2017] No. 249), in order to further regulate the rational use of drugs in Beijing, the following requirements are now proposed. 1. Medical institutions must establish and improve key monitoring drug management systems The main person in charge of each medical institution is the first person responsible for the key drug monitoring and management of the organization. All medical institutions shall formulate key management drug management systems, catalogues and work processes of this institution, organize and carry out special work of key monitoring drug management of their own units, monitor the clinical application of key monitoring drugs, regularly analyze, evaluate and report monitoring data and publicize relevant Information, propose interventions and improvement measures, and provide training for medical personnel on relevant regulations and rules and regulations for drug monitoring. Second, the main measures for medical institutions to carry out key monitoring drug management (1) Formulating a list of key monitoring drugs The main characteristics of key monitoring drugs are: non-treatment of certain diseases, insufficient evidence of clinical efficacy, lack of recommendation for the diagnosis and treatment of authoritative diseases, or lack of pharmacoeconomic advantages, and large amount or high purchase amount. According to the main characteristics of key monitoring drugs, all medical institutions shall rank the top 100 drugs (common names) according to the amount of use of the institution, and combine the characteristics of each department of the institution to formulate key monitoring drugs of this institution according to the principles of effective, safe and economic rational drug use. The catalogue (see Appendix for the template), the catalogue number is not less than 15 (including chemicals, proprietary Chinese medicines and biopharmaceuticals). The catalogue is dynamically monitored and adjusted, and is updated and publicized according to the above principles according to the drug use. (II) Strengthening the dynamic monitoring of the purchase and use of key monitoring varieties All medical institutions shall establish and improve the internal control mechanism for key monitoring drug management, strengthen the monitoring of key monitoring drug selection, procurement, prescription, adjustment, clinical application, evaluation, etc., and further improve the dynamic monitoring and super-warning mechanism of key monitoring drugs. . All medical institutions shall set up the control indicators of key monitoring drugs in the clinical department as the unit and include them in the performance appraisal of the department; further improve the key monitoring and monitoring mechanism for drug use, and enter the top 20 key monitoring drugs for medical institutions for 3 consecutive months. Take measures such as interviewing, restricting the use or stopping sales; quarterly, publicly display the clinical departments and doctors who use the key monitoring drugs in an over-the-counter manner, criticize and educate when necessary, and reward and punish with the performance, evaluation, promotion, etc. of departments and individuals. Measures are linked. Some relevant industry sources said that although the Beijing Municipal Health Planning Commission did not announce the specific list of key monitoring varieties, it only requires that the number of varieties monitored by various medical institutions should be no less than 15 kinds, but the industry generally believes that The implementation of the "Notice" will make the structural adjustment of the medication habits of the Beijing Top Three Hospital, and the auxiliary medication and irrational medication will be gradually cleared out of the bureau. Third, the key requirements for monitoring drug management work requirements (1) The Municipal Health and Family Planning Commission is responsible for guiding the supervision and management of key monitoring drugs in medical institutions throughout the city. The Municipal Hospital Administration is responsible for the supervision and administration of municipal hospitals, and the district health and family planning committees are responsible for the supervision and management of medical institutions within their respective jurisdictions. By the end of 2017, the proportion of public hospitals (excluding traditional Chinese medicine decoction pieces) will be reduced to about 30% by administrative districts, and the increase in total drug costs should be significantly lower than the increase in the number of emergency departments and discharged patients. (2) The health and family planning administrative departments at all levels should attach great importance to the key monitoring and control of drug management, raise awareness and strengthen responsibilities, and make this work an important part of the city's drug management work this year and in the next few years. The administrative departments of health and family planning at all levels should make full use of informatization means, monitor the medical equipment's key monitoring drug catalogues and clinical use, and organize on-site supervision and inspection in a timely manner; publicize the results of monitoring and evaluation and on-site inspections in conjunction with actual conditions, and serve as medical care. Important content such as performance appraisal and rating review of the organization. The administrative departments of health and family planning at all levels may take measures such as notification, rectification within a time limit, and talks with the principal responsible persons of the institution for the implementation of the key monitoring drug management work; for medical institutions that have serious problems and are still not in place for rectification, Seriously pursue the responsibility of the responsible person. Eas Soft Label,Eas Am Label,Am Eas Tag,Rf Soft Label Wenzhou Boshine Electronic Security Co. Ltd , https://www.boshine.com